Regeneron Pharmaceuticals/ US75886F1075 /
2024-03-28 8:59:57 PM | Chg. -4.18 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
962.31USD | -0.43% | 23,057 Turnover: 22.19 mill. |
-Bid Size: - | -Ask Size: - | 105.64 bill.USD | - | 25.98 |
GlobeNewswire
03-22
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
GlobeNewswire
03-20
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
GlobeNewswire
03-18
CIO Celebrates Innovations in Business Technology with 2024 CIO 100 & Hall of Fame Awards
GlobeNewswire
03-13
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientif...
GlobeNewswire
03-11
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High C...
GlobeNewswire
03-08
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) a...
GlobeNewswire
02-28
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portf...
GlobeNewswire
02-23
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflam...
GlobeNewswire
02-23
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inf...
GlobeNewswire
02-22
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights R...
GlobeNewswire
02-21
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28...
GlobeNewswire
02-21
Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Re...
GlobeNewswire
02-16
Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
GlobeNewswire
02-16
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
GlobeNewswire
02-02
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
GlobeNewswire
02-02
Linvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
GlobeNewswire
01-30
Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platf...
GlobeNewswire
01-25
Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year...
GlobeNewswire
01-25
Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year an...